glimepiride: Clinical Trials

83 trials of glimepiride, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

66 completed, 12 terminated, 3 withdrawn, 1 not yet recruiting. 83 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 383Completed 66, Terminated 12, Withdrawn 3, Not yet recruiting 1, Unknown 1
Phase 23Completed 3

Follow glimepiride: new trials by email Literature Review of glimepiride trials Research Report on glimepiride

Trials (filtered) newest first · largest first

All 83 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.
Glimepiride (oral), Placebo - Type 2 Diabetes Mellitus (T2DM), Chronic Heart Failure (CHF)
Phase 3Not yet recruitingTongji Hospital14842026-01-012025-12-17
Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure
A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), (A2) Glimepiride/Vildagliptin/Metformin - Type 2 Diabetes
Phase 3CompletedLaboratorios Silanes S.A. de C.V.1622023-03-212025-06-10
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
Sotagliflozin (SAR439954), Glimepiride, Metformin - Type 2 Diabetes Mellitus
Phase 3CompletedLexicon Pharmaceuticals9542017-12-012021-05-11
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
ITCA 650 20/60 mcg/day, Empagliflozin (oral), Glimepiride (oral) - Diabetes Mellitus, Type 2
Phase 3TerminatedIntarcia Therapeutics2452017-03-032019-03-07
Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes
triple combination therapy, Stepwise add-on therapy - Diabetes Mellitus, Type II
Phase 3UnknownKorea University Anam Hospital1042016-12-012016-10-27
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Bexagliflozin, Placebo for Bexagliflozin, Glimepiride - Type 2 Diabetes Mellitus
Phase 3CompletedTheracos4262016-08-152021-05-27
DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)
Metformin, Glimepiride - Diabetes Mellitus
Phase 3WithdrawnDiabetes Frail Ltd2016-02-012017-07-28
A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo matching ertugliflozin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC5062015-12-162018-12-07
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
Saxagliptin, Dapagliflozin, Glimepiride - Diabetes
Phase 3CompletedAstraZeneca4442015-08-142020-06-23
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
Ertugliflozin, Sitagliptin, Placebo to Ertugliflozin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC2912014-09-232018-09-13
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Matching Placebo to Ertugliflozin 5 mg, Matching Placebo to Ertugliflozin 10 mg, Matching Placebo to sitagliptin 100 mg - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC12332014-04-222018-09-12
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo for ertugliflozin 5 mg - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC4642014-03-122018-09-13
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to Ertugliflozin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC6212013-12-132018-09-10
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
Ertugliflozin 5 mg, Ertugliflozin 10 mg, Placebo to Ertugliflozin - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC4612013-10-092017-09-29
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)
Omarigliptin, Glimepiride, Omarigliptin Placebo - Type 2 Diabetes Mellitus
Phase 3TerminatedMerck Sharp & Dohme LLC652013-07-082018-09-10
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
Omarigliptin, Sitagliptin, Placebo to omarigliptin - Type 2 Diabetes
Phase 3CompletedMerck Sharp & Dohme LLC6422013-06-132018-09-10
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide) - Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Phase 3CompletedGRADE Study Group78502013-05-012026-02-10
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
TAK-875, TAK-875 Placebo, Glimepiride - Diabetes Mellitus, Type 2
Phase 3TerminatedTakeda332013-04-012016-06-01
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
ITCA 650 60 mcg/day, glimepiride - Type 2 Diabetes
Phase 3WithdrawnIntarcia Therapeutics2013-02-012012-12-25
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes
ITCA 650, glimepiride - Type 2 Diabetes
Phase 3WithdrawnIntarcia Therapeutics2013-02-012012-12-25

Showing 20 of 83. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (80)  ·  Diabetes Mellitus (28)  ·  Glucose Metabolism Disorders (5)  ·  Diabetes Mellitus, Lipoatrophic (4)  ·  Dyslipidemias (4)  ·  Atherosclerosis (2)  ·  Insulin Resistance (2)  ·  Cardiovascular Diseases (1)  ·  Coronary Disease (1)  ·  Endocrine System Diseases (1)  ·  Frailty (1)  ·  Hypercholesterolemia (1)  ·  Hyperlipidemias (1)  ·  Hypertension (1)  ·  Hypoglycemia (1)

Sponsors

Merck Sharp & Dohme LLC (20)  ·  Novo Nordisk A/S (9)  ·  Takeda (9)  ·  Sanofi (7)  ·  Boehringer Ingelheim (5)  ·  GlaxoSmithKline (4)  ·  AstraZeneca (3)  ·  Eli Lilly and Company (3)  ·  Intarcia Therapeutics (3)  ·  Novartis Pharmaceuticals (3)  ·  Astellas Pharma Inc (1)  ·  Canadian Heart Research Centre (1)  ·  Diabetes Frail Ltd (1)  ·  GRADE Study Group (1)  ·  Gilead Sciences (1)

Countries

United States (31)  ·  Mexico (16)  ·  Germany (14)  ·  India (14)  ·  Russia (14)  ·  Canada (13)  ·  Poland (13)  ·  Philippines (12)  ·  Romania (12)  ·  Spain (12)  ·  Argentina (11)  ·  Hungary (11)  ·  South Africa (11)  ·  South Korea (11)  ·  United Kingdom (11)

Top investigators

Alan Sinclair (1)  ·  Ana L Flores Barranco, M.D (1)  ·  Carlos Abraira, MD (1)  ·  Christine Kliebe-Frisch, MD (1)  ·  David M Nathan, MD (1)

Results publications

PMID 23010561, PMID 25504028, PMID 21450987, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 19245711, PMID 19491536, PMID 19878259, PMID 21883806, PMID 22055210, PMID 22193143, PMID 22862847, PMID 23186975, PMID 24561125, PMID 32700393, PMID 34213819, PMID 21209033, PMID 31064361, PMID 18539917, PMID 19491535, PMID 19744248, PMID 19898642, PMID 19930006, PMID 22234149, PMID 24843617, PMID 28683300, PMID 30880443, PMID 33367811, PMID 36763328, PMID 38770818, PMID 40020703, PMID 11347758, PMID 14583175, PMID 16033281, PMID 16043738, PMID 16504835, PMID 16627388, PMID 16784922, PMID 17101640, PMID 17327456, PMID 17392540, PMID 18284434, PMID 18378631, PMID 18406632, PMID 18413496, PMID 18469202, PMID 18539916

NIH funding

2009 (4), 2005 (1), 2014 (1), 2016 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), U01DK098246 (1)